The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.
Table
|
S.No |
Suspected Drug |
Indication |
Adverse Reaction(s) |
|
1 |
Ranibizumab |
Neovascular Age-Related Macular Degeneration (AMD), Visual impairment due to Diabetic Macular Edema (DME), visual impairment due to Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM).
|
Myocardial Infarction |
|
2 |
Amphotericin B |
Life threatening fungal infections including histoplasmosis, coccidioidomycosis, paracoccidioidomycosis, blastomycosis, aspergillosis, cryptaococcosis, mucormycosis, sporotrichosis and candidiasis; visceral and mucocutaneous leishmaniasis unresponsive to pentavalent antimony compounds; severe meningitis. perioral candidiasis. |
Bone Marrow Depression |
|
3 |
Doxorubicin |
Soft tissue and bone sarcomas, acute leukemia, malignant lymphoma, Hodgkin’s diseases, breast carcinoma, small cell carcinoma of lungs, AIDS-related Kaposi’s sarcoma, multiple myeloma. Gastrointestinal tract carcinoma, bladder cancer, ovarian carcinoma, acute myeloblastic leukemia, thyroid carcinoma, neuroblastoma. |
Photosensitivity Reaction |
|
4 |
Crizotinib |
Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) that is Anaplastic Lymphoma Kinase (ALK) – positive. |
Pneumonitis, Hepatic Encephalopathy |
Healthcare professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse reaction(s) while prescribing/consuming above suspected drugs and report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/
Medicines Side Effect Reporting Form for Consumer (https://www.ipc.gov.in) or by PvPI Helpline No. 1800-180-3024.